Slide 1: EQiTX
0? EQiTX
Slide 2: Capital structure
Capital structure ° Ordinary Shares (31/10/2003) 24,564,170 ¢ Options ~ Listed * 17,000,000 (exercise price $0.20, expire 30/6/2007) ~ Employee Option Plan * 2,050,000 (exercise price $0.20 - $0.75, expire 14/5/2008) ~ Other * 389,250 (exercise price $0.40 - $1.00, expire 7/6/2006) ¢ Top 20 Sharehol
Slide 3: Ability to deliver: Personnel
B Ability:to:deliver Personnel oard Executive Solomon Majteles . (Chairman) Dr. Noel Chambers (CEO) Brian Nathanson « Dr. Julie-Anne White (MD. ZingoTX) Prof. Mark von Itzstein * Stephen Brown (Co. Secretary) Hilton Nathanson Dr. Kevin Fahey Geoff Harland Scientific Advisory Board « Professor Pat Ho
Slide 4: Investment model
Investment.model Investment Structure & Commercialisation Strategies
Slide 5: Gingerol Vaccine
Gingerol Vaccine ZingoT Project Ply Lid VacTX Ply Lid
Slide 6: Investment model: Commercialisation Strategies
Investment:model Commercialisation Strategies ¢ License to large pharma ~ What they want ~ How they operate « IPO « Trade Sale
Slide 7: Projects and Selection Criteria
Investments Projects and Selection Criteria
Slide 8: Project Selection Criteria
Investments Project Selection Criteria * Selecting the right research ~ Targets an unmet human medical need ~ Big and growing markets (e.g. aging population) ~ Clear competitive advantages (e.g. safety, cost , convenience, etc) ~ Proof of concept completed in animals ¢ Ready for development * EQiTX
Slide 9: Project I – Gingerols (ZingoTX Pty Ltd)
Project | — Gingerols (ZingoTX Pty Ltd) Novel ‘gingerol’ compound library Targets pain and inflammation ($US 16B market) Acute and Chronic pain management ~ @.g. cancer, neuropathy, back pain inflammation ~ e.g. arthritis, trauma, infectious diseases Other potential uses ~ €.g. urinary incontinence,
Slide 10: Problems with Current Pain Treatments
Investments Problems with Current Pain Treatments ¢ Opioids (e.g. Morphine) ~ Addictive ~ Nausea ~ Constipation * Non-Steroidal Anti-inflammatory Drugs (NSAIDS) ~ Bleeding and ulceration in the intestinal tract ~ Platelet function is disturbed (coagulation) ~ Kidney function can be compromised ~ Som
Slide 11: Advantages - Gingerols
investments Advantages - Gingerols * Studies in experimental animal models show gingerois are; ~ active in models of pain, including some not adequately covered by current medicines ~ not addictive ~ free of adverse side effects
Slide 12: Gingerols - Other Therapeutic Opportunities
Investments Gingerols - Other Therapeutic Opportunities ¢ Urinary incontinence (urge incontinence) ~ Affects approximately 200 million people world-wide ~ More than 50 million people in the U.S_A., Europe and Japan ~ Less than 20% presently receiving treatment ~ Growing market as prevalence increase
Slide 13: ZingoTX Pty Ltd - Board
Investments ZingoTX Pty Ltd - Board Mr Conrad Crisafulli (Chairman) Dr Julie-Anne White (Managing Director) Dr Kevin Fahey Professor Les Field Mr Bruce McGilvray
Slide 14: ZingoTX Timelines and Funding
Investments Commitment = $2.36 Million ZingoTX Timelines and Funding Final Equity = 68% 195% 40 5% 50.5% 56.0% $680,000 $620,000 months 6 12 18 24 30 » Research strategy Lead compound selection Pre-clinical testing and refinement Finalise pre-clinical testing and expand therapeutic targets Initial h
Slide 15: Project – Lipopeptide Vaccines (VacTX Pty Ltd)
Investments Project 2 — Lipopeptide Vaccines wacrx pry us) ¢ CRC-VT Board has agreed terms ~ Finalisation of agreements expected in due course. ¢ Enabling lipopeptide vaccine technology ~ Improved vaccines for infectious diseases and cancer, and vaccines that will compete with existing monoclonal an
Slide 16: Traditional Viral Vaccines vs Lipopeptide Viral Vaccines
Traditional Viral Vaccines —— Grow virus v in cultured celis Kill & formulate v Biological Manufacturing Process lraportant virus component Chemical Manufacturing Process Lipopeptide Viral Vaccines Synthesize viral “component chemically aa Add hel; ( — and enhancer \ chemicals Totally synthetic vacc
Slide 17: Superior Immune Response
Superior Immune Response influenza virus vaccines: 15 mon 100 7 80 - 3 a 6- 2 a oe 7 | 6 40 5 & 20 - 0 T 10 100 Effector : Target Ratio ths post-vaccination Influenza Vaccines: Lipopeptide Vaccine A —fs— __Lipopeptide Vaccine B —*— Conventional Vaccine —F— Alternative Peptide Vaccine —s—___ Control
Slide 18: Advantages – Lipopeptide Vaccines
Investments Advantages — Lipopeptide Vaccines Very potent, specific and safe Convenient long-term therapy Chemically pure and soluble ~ easier regulatory pathway Substantially cheaper than therapeutic antibodies Can be administered intra-nasally — most vaccines are injectable ~ needle sticks & hazar
Slide 19: VacTX's Business Strategy
Investments VacTX’s Business Strategy * Provide a contract service to make peptides immunogenic — cash flow * Collaboration or Joint Venture with companies/institutes with ‘interesting’ vaccine epitopes .. * Out-license some prototype lipopeptide vaccines cae * In-license, if necessary, commercially
Slide 20: Thank you!
EQiTX Thank you!